OncoMatch/Clinical Trials/NCT06925737
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Is NCT06925737 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Ifinatamab deruxtecan and Docetaxel for prostate cancer.
Treatment: Ifinatamab deruxtecan · Docetaxel · Prednisone · Rescue Medication — Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer overall and live longer without the cancer growing or spreading than people who receive chemotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Metastatic disease required
Prior therapy
Must have received: androgen receptor pathway inhibitor
Has received prior treatment with 1 or 2 androgen receptor pathway inhibitors (ARPIs) and progressed during or after at least 8 weeks of treatment
Cannot have received: taxane-based chemotherapy
Exception: for metastatic castration-resistant prostate cancer (mCRPC)
Has received prior treatment with a taxane-based chemotherapy agent for metastatic castration-resistant prostate cancer (mCRPC)
Cannot have received: antibody-drug conjugate (exatecan derivative (e.g., trastuzumab deruxtecan))
Exception: prior discontinuation due to treatment-related toxicities
Has had prior discontinuation of an antibody drug conjugate (ADC) that consists of an exatecan derivative (eg, trastuzumab deruxtecan) due to treatment-related toxicities
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic in Arizona - Phoenix ( Site 0044) · Phoenix, Arizona
- City of Hope Comprehensive Cancer Center ( Site 0049) · Duarte, California
- City of Hope Lennar Foundation Cancer Center ( Site 0059) · Irvine, California
- Moores Cancer Center ( Site 0010) · La Jolla, California
- Cedars-Sinai Medical Center ( Site 0068) · Los Angeles, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify